A5025066980- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Screening and Detection
- Radiomics and Machine Learning in Medical Imaging
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Metastasis and carcinoma case studies
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Cervical Cancer and HPV Research
- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
Fédération Francophone de Cancérologie Digestive
2016-2025
Université de Bourgogne
2015-2025
Inserm
2016-2025
Centre de recherche Translationnelle en Médecine moléculaire
2019-2024
Université Bourgogne Franche-Comté
2019
Université Paris Cité
2016-2018
Hôpital Européen Georges-Pompidou
2016-2018
Centre Georges François Leclerc
2018
CHU Dijon Bourgogne
2017
Centre Jean Perrin
2016
The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) microsatellite-stable (MSS) subgroups resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III cancer with separate analysis MSI MSS tumors receiving adjuvant FOLFOX +/- cetuximab two therapy trials.
The prognostic value of BRAF and KRAS mutations in patients who have undergone resection for colon cancer been treated with combination leucovorin, fluorouracil, oxaliplatin (FOLFOX)-based adjuvant chemotherapy is controversial, possibly owing to a lack stratification on mismatch repair status.To examine the effect stage III FOLFOX or without cetuximab.This study included available tumor blocks resected adenocarcinoma participated between December 2005 November 2009 PETACC-8 phase randomized...
The objective of this study was to build and validate a radiomic signature predict early poor outcome using baseline 2-month evaluation CT compare it the RECIST1·1 morphological criteria defined by changes in homogeneity borders.This is an ancillary from PRODIGE-9 multicentre prospective for which 491 patients with metastatic colorectal cancer (mCRC) treated 5-fluorouracil, leucovorin irinotecan (FOLFIRI) bevacizumab had been analysed. In 230 patients, computed texture analysis performed on...
The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial.
Objective Diagnostic tests, such as Immunoscore, predict prognosis in patients with colon cancer. However, additional prognostic markers could be detected on pathological slides using artificial intelligence tools. Design We have developed a software to detect tumour, healthy mucosa, stroma and immune cells CD3 CD8 stained slides. The lymphocyte density surface area were quantified automatically the tumour core (TC) invasive margin (IM). Using LASSO algorithm, DGMate (DiGital tuMor...
Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer after induction chemotherapy. Patients and Methods In this open-label, phase III, randomized controlled trial, we compared the tumor control duration (TCD) observed no (observation) CFI subsequent to chemotherapy 12 cycles of fluorouracil, leucovorin, irinotecan plus bevacizumab. After disease progression, regimen was repeated eight...
We know of no data on the prognostic value primary tumor location (PTL) according to BRAF, RAS, and microsatellite instability (MSI) status in patients who have undergone resection for colon cancer (CC) been treated with current standard adjuvant chemotherapy.To determine predictive PTL MSI stage III CC receiving treatment FOLFOX (folinic acid [leucovorin calcium], fluorouracil, oxaliplatin) or without cetuximab.This post hoc analysis included available blocks resected adenocarcinoma...
Previous pharmacogenetic studies have shown the prognostic impact of several rare dihydropyrimidine dehydrogenase gene (DPYD) variants on fluorouracil-related adverse events (fluorouracil AEs). However, conflicting results highlight need for prospective validation in large, homogeneous patient populations uniformly treated with current standard combination therapies used colon cancer (CC).To determine DPYD fluorouracil AEs patients stage III CC a fluorouracil, leucovorin, and oxaliplatin...
Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4-ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over gemcitabine for overall survival. The high limiting oxaliplatin-related neurotoxicity supports evaluation an stop-and-go strategy sequential in mPC.In this phase II study, patients were randomly assigned to receive either 6 months FOLFIRINOX (arm A), 4...
Abstract Purpose: The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity colon cancer. Intratumor (ITH) is new frontier for refining prognostication and treatment resistance. This study aims at deciphering transcriptomic ITH cancer its potential prognostic implications. Experimental Design: We deconvoluted profiles 1,779 tumors from PETACC8 trial 155 cell lines as weighted sums four CMSs, using Weighted In Silico Pathology...
Only 1 randomized clinical trial has shown the superiority of immune checkpoint inhibitors in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) first-line setting.To determine whether avelumab (an anti-programmed cell death ligand antibody) improves progression-free survival (PFS) compared standard second-line chemotherapy dMMR/MSI mCRC.The SAMCO-PRODIGE 54 is a national open-label phase 2 that was conducted from April...
A dramatic increase in the incidence of diffuse form gastric adenocarcinomas and particularly signet ring cell carcinomas has been observed Western countries. Evidence is accruing that may have inherent chemo resistance leaving many clinicians unsure benefits delaying surgery to pursue a neoadjuvant approach. PRODIGE-19-FFCD1103-ADCI002 prospective multicentre controlled randomised phase II/III trial comparing current standard care perioperative chemotherapy (2x3 cycles Epirubicin,...
4000 Background: Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis (5-year overall survival [OS] <5%). Our previous trial (PRODIGE4-ACCORD11) has demonstrated the superiority of 6-month [m] chemotherapy with FOLFIRINOX over gemcitabine in terms progression-free [PFS] (6.4 vs. 3.3 m; HR: 0.47; 95%CI: 0.37-0.59; p<0.001) and OS (11.1 6.8 0.57; 0.45-0.73; p<0.001), at expense higher toxicity, notably cumulative, often limiting, peripheral neuropathy oxaliplatin. In this...